This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Arp2/3 | |
|---|---|
| Name | Actin-related protein 2/3 complex |
| Organism | Eukaryota |
Arp2/3 is a seven-subunit protein complex that nucleates branched actin filament networks essential for cell motility, endocytosis, and morphogenesis. First characterized in eukaryotic cytoskeleton studies, the complex integrates signals from surface receptors, small GTPases, and nucleation-promoting factors to control dynamic actin assembly during processes studied by researchers at institutions such as Harvard University, Max Planck Society, Cold Spring Harbor Laboratory, Salk Institute for Biological Studies, and Stanford University. Key contributors to Arp2/3 research include scientists affiliated with Nobel Prize-winning themes and major projects funded by organizations like the National Institutes of Health, Wellcome Trust, and Howard Hughes Medical Institute.
The complex comprises seven subunits historically designated ARP2, ARP3, and ARPC1–5, with structural insights provided by groups at European Molecular Biology Laboratory, MRC Laboratory of Molecular Biology, University of Cambridge, Yale University, and California Institute of Technology. Cryo-electron microscopy and X-ray crystallography studies from teams at University of Oxford, Massachusetts Institute of Technology, Rockefeller University, University of Zurich, and University of Basel revealed that ARP2 and ARP3 are actin-related proteins that mimic an actin dimer, while ARPC1–5 form a supporting scaffold similar to subcomplexes characterized in analyses by EMBO, American Society for Cell Biology, and Biophysical Society. Comparative genomics performed by researchers at European Bioinformatics Institute, Broad Institute, Stanford Genome Technology Center, Wellcome Sanger Institute, and University of Tokyo showed conservation across fungi, plants, animals, and protists, with variations studied in labs such as University of California, San Francisco and University of Edinburgh.
Functional assays developed by investigators at Johns Hopkins University, Columbia University, University of Michigan, University of Pennsylvania, and Duke University demonstrated that the complex binds to the side of a preexisting filament and nucleates a new filament at a characteristic ~70° angle, a phenomenon further characterized by collaborators at University of Chicago, Princeton University, Brown University, and Northwestern University. Biochemical reconstitution efforts involving teams at University of California, Berkeley, ETH Zurich, University of Washington, McGill University, and University of British Columbia established the sequence of events where nucleation-promoting factors and ATP binding drive conformational changes first described in studies from Scripps Research, University of Iowa, and University of North Carolina at Chapel Hill. Models integrating data from Los Alamos National Laboratory and Argonne National Laboratory have been used by consortia including Howard Hughes Medical Institute investigators to simulate actin branching kinetics and filament network mechanics in contexts studied by NASA-funded cell mechanics programs.
Arp2/3 activity is regulated by nucleation-promoting factors such as WASP family proteins, characterized in work from University College London, Imperial College London, University of Helsinki, University of Geneva, and Karolinska Institute. Regulators include WAVE, N-WASP, Scar, and Cortactin, with biochemical interactions mapped by laboratories at Max Planck Institute for Molecular Cell Biology and Genetics, Institut Pasteur, CNRS, University of Groningen, and University of Bonn. Small GTPases like Cdc42 and Rac link surface receptors from signaling pathways described at Yale School of Medicine, University of California, San Diego, Vanderbilt University, and University of Texas Southwestern Medical Center to Arp2/3 activation. Inhibitors and modulators identified by pharmaceutical collaborations with GlaxoSmithKline, Pfizer, Roche, Novartis, and Merck have informed chemical biology approaches used in structural and cellular assays at Baylor College of Medicine, Weill Cornell Medicine, and Icahn School of Medicine at Mount Sinai.
Cellular roles for Arp2/3 have been mapped in lamellipodia formation, endocytic vesicle trafficking, phagocytosis, and pathogen propulsion, with seminal contributions from teams at University of Cambridge, University of Oxford, Heidelberg University, University of Freiburg, and Tokyo Institute of Technology. Live-cell imaging and super-resolution microscopy work by groups at University of California, Santa Barbara, University of Illinois at Urbana-Champaign, University of Toronto, McMaster University, and University of Melbourne showed Arp2/3 localization at leading edges, cortical actin, and internal membrane platforms. Comparative cell biology across model organisms—studied at Princeton University, University of Copenhagen, University of Zurich, University of California, Davis, and Carnegie Institution for Science—demonstrated conserved and specialized roles in yeast, Dictyostelium, plants, and metazoans. Connections to cytoskeletal cross-talk with myosin II and microtubule plus-end tracking proteins were investigated by teams at University of Minnesota, University of Colorado Boulder, University of Florida, Rutgers University, and University of Southampton.
Genetic and developmental studies implicate Arp2/3 in processes such as neuronal migration, epithelial morphogenesis, immune cell function, and wound healing; major developmental biology labs at Harvard Medical School, Yale School of Medicine, Stanford School of Medicine, Princeton University, and Columbia University Medical Center have published on related phenotypes. Dysregulation of Arp2/3 is linked to immunodeficiencies associated with WASP mutations uncovered by investigators at National Institute of Allergy and Infectious Diseases, and to cancer cell invasion and metastasis characterized in research from MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center, and Mayo Clinic. Pathogen exploitation of Arp2/3 during intracellular motility was described in foundational studies by groups at Pasteur Institute, University of California, Irvine, Johns Hopkins Bloomberg School of Public Health, London School of Hygiene & Tropical Medicine, and Cold Spring Harbor Laboratory, influencing therapeutic research at biotechnology firms like Genentech and Biogen.
Discovery and characterization of Arp2/3 involved biochemical fractionation, actin polymerization assays, electron microscopy, and genetics performed at Stanford University School of Medicine, University of Cambridge, European Molecular Biology Laboratory, Cold Spring Harbor Laboratory, and University of California, San Diego. Key methodological advances—TIRF microscopy, cryo-EM, single-molecule fluorescence—were developed in facilities at Cornell University, University of Oxford, Harvard University, Max Planck Institute for Biophysical Chemistry, and Lawrence Berkeley National Laboratory, enabling reconstitution studies by consortia including HHMI and core facilities at Wellcome Trust Sanger Institute. Historical perspectives on Arp2/3 trace through major conferences such as the Gordon Research Conferences, EMBO Conference on Cytoskeleton, ASCB Annual Meeting, and milestone reviews published by editorial offices at Nature, Science, Cell, Journal of Cell Biology, and Molecular Biology of the Cell.
Category:Cytoskeletal proteins